<DOC>
	<DOCNO>NCT00772343</DOCNO>
	<brief_summary>Primary objective : To compare event rate CDI group assign ACAM-CDIFF™ vaccine versus placebo 9 week period third dose study vaccine subject first episode CDI receive antibiotic standard care . Secondary objective : To evaluate safety dose group ACAM-CDIFF™ vaccine versus placebo subject first episode CDI receive antibiotic standard care .</brief_summary>
	<brief_title>Study Clostridium Difficile Toxoid Vaccine ( ACAM-CDIFF™ ) Subjects With Clostridium Difficile Infection</brief_title>
	<detailed_description>This study design primarily obtain information preliminary efficacy , safety immunogenicity ACAM-CDIFF™ vaccine , compare placebo subject experience first event CDI treat antibiotic standard care . This study conduct United States United Kingdom . Adult subject limit chronic disease , currently receive treatment first episode CDI enrol trial . Subjects require able take oral antibiotic .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Adult subject , 18 85 year old , understand risk benefit participation provide write informed consent study . 2 . Subjects experience first event CDI diagnose within last 10 day . 3 . Subjects medically stable . 4 . Subjects willing able comply study procedure visit schedule outline . 1 . Subjects currently treatment recurrence CDI . 2 . Subjects currently recently treat immunoglobulin therapy . 3 . Pregnant breast feeding female . 4 . Concurrent , acutely lifethreatening disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Diarrhea</keyword>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>Clostridium difficile toxoid</keyword>
</DOC>